In last trading session, Silence Therapeutics Plc ADR (NASDAQ:SLN) saw 0.59 million shares changing hands with its beta currently measuring 0.85. Company’s recent per share price level of $9.10 trading at -$0.2 or -2.15% at ring of the bell on the day assigns it a market valuation of $327.05M. That closing price of SLN’s stock is at a discount of -97.69% from its 52-week high price of $17.99 and is indicating a premium of 50.0% from its 52-week low price of $4.55. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 21470.0 shares which gives us an average trading volume of 60.99K if we extend that period to 3-months.

For Silence Therapeutics Plc ADR (SLN), analysts’ consensus is at an average recommendation of a Buy while assigning it a mean rating of 1.00. Splitting up the data highlights that, out of 5 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 5 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of $Southwestern Energy Company in the current quarter.

Silence Therapeutics Plc ADR (NASDAQ:SLN) trade information

Upright in the red during last session for losing -2.15%, in the last five days SLN remained trading in the red while hitting it’s week-highest on Friday, 11/17/23 when the stock touched $9.10 price level, adding 7.89% to its value on the day. Silence Therapeutics Plc ADR’s shares saw a change of -40.33% in year-to-date performance and have moved -1.09% in past 5-day. Silence Therapeutics Plc ADR (NASDAQ:SLN) showed a performance of 23.31% in past 30-days. Number of shares sold short was 0.14 million shares which calculate 8.62 days to cover the short interests.

Wall Street analysts have assigned a consensus price target of $34.00 to the stock, which implies a rise of 73.24% to its current value. Analysts have been projecting $15.00 as a low price target for the stock while placing it at a high target of $75.00. It follows that stock’s current price would drop -724.18% in reaching the projected high whereas dropping to the targeted low would mean a loss of -64.84% for stock’s current value.

Silence Therapeutics Plc ADR (SLN) estimates and forecasts

Statistics highlight that Silence Therapeutics Plc ADR is scoring comparatively lower than the scores of other players of the relevant industry. The company added 52.17% of value to its shares in past 6 months, showing an annual growth rate of -3.21% while that of industry is 10.50. Apart from that, the company came lowering its revenue forecast for fiscal year 2023.

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -77.11% during past 5 years.

SLN Dividends

Silence Therapeutics Plc ADR is more likely to be releasing its next quarterly report in December and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.

Silence Therapeutics Plc ADR (NASDAQ:SLN)’s Major holders

Insiders are in possession of 31.87% of company’s total shares while institution are holding 52.36 percent of that, with stock having share float percentage of 76.86%. Investors also watch the number of corporate investors in a company very closely, which is 52.36% institutions for Silence Therapeutics Plc ADR that are currently holding shares of the company. Lombard Odier Asset Management (USA) Corp is the top institutional holder at SLN for having 4.12 million shares of worth $22.66 million. And as of Jun 29, 2023, it was holding 13.77% of the company’s outstanding shares.

The second largest institutional holder is Lombard Odier Asset Management (Europe) Ltd, which was holding about 3.42 million shares on Jun 29, 2023. The number of shares represents firm’s hold over 11.41% of outstanding shares, having a total worth of $18.78 million.